An experiment about processing, not a finished therapy
Thurston and colleagues conducted a double-masked, placebo-controlled crossover trial in premenopausal women with hypoactive sexual desire disorder. Forty participants were randomized and 32 completed both visits. Brain imaging assessed responses to sexual and facial-attraction stimuli during the experimental conditions.
The researchers reported changes in activity in several brain regions, with some associations between those responses and measures of distress or aversion. This gives investigators information about possible mechanisms. It does not turn a scanner result into a demonstrated, lasting improvement in everyday sexual wellbeing.
Why a crossover helps—and where it stops
Comparing conditions within the same person can reduce the influence of stable differences between participants. Masking and a placebo comparison also strengthen the question being tested. They cannot make a short observation answer a long-term question, or make one carefully selected group represent everyone with low desire.
The paper reports no adverse effects in this experiment. That limited observation should not be read as proof that repeated or unsupervised exposure is safe. In S7’s interpretation, promising mechanistic evidence warrants further study; it does not replace trials centered on sustained benefits, harms and outcomes that matter to patients.
A useful evidence-reading checklist
Before accepting a benefit claim, ask whether the headline describes the actual outcome, whether the comparison was fair, and whether the follow-up matches the claim’s timescale. A brain signal, a questionnaire score and a real-world clinical outcome are different kinds of evidence. Keeping them separate makes research easier to understand without dismissing early discoveries.
This is an original S7 educational discussion of a previously published study, not medical advice or a recommendation to use kisspeptin. It supplies no treatment, administration or cycling instructions.